

**AWARD NUMBER:** W81XWH-18-1-0615

**TITLE:** Novel Neuroimaging Assessments of Glymphatic Disruption in Humans, a Plausible Key Pathophysiological Mechanism for CNS Lupus

**PRINCIPAL INVESTIGATOR:** Mark DiFrancesco, PhD

**CONTRACTING ORGANIZATION:** Children's Hospital Medical Center

**REPORT DATE:** OCTOBER 2021

**TYPE OF REPORT:** Annual Progress

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release; distribution is unlimited.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> OCTOBER 2021		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 01 Sept 2020 – 31 Aug 2021	
<b>4. TITLE AND SUBTITLE</b>  Novel Neuroimaging Assessments of Glymphatic Disruption in Humans, a Plausible Key Pathophysiological Mechanism for CNS Lupus				<b>5a. CONTRACT NUMBER</b> W81XWH-18-1-0615	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Mark DiFrancesco, PhD & Hermine Brunner, MD  E-Mail: <a href="mailto:mark.difrancesco@cchmc.org">mark.difrancesco@cchmc.org</a> & <a href="mailto:Hermine.brunner@cchmc.org">Hermine.brunner@cchmc.org</a>				<b>5d. PROJECT NUMBER</b> 0011201298USA	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Children's Hospital Medical Center 3333 Burnet Ave Cincinnati, OH 45229-3026				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
				<b>13. SUPPLEMENTARY NOTES</b>	
<b>14. ABSTRACT</b> This project develops and applies novel brain imaging to probe a new route by which SLE can lead to neuronal degradation. It adds the glymphatic system to the array of neurovascular components that plausibly underlie the pathobiology of lupus, even before overt neuro-psychiatric syndromes. We have generated a combination of neuroimaging protocols allowing regional characterization of glymphatic structural and functional integrity. A vascular space occupancy (VASO) imaging sequence is being used to measure amplitude of fluctuations in vascular volume driven by respiratory and cardiac cycles, a purported mechanism for glymphatic flow. Protocol development led to a focus on detecting the glymphatic-specific microenvironment by adopting "microdynamic" imaging methods based on relaxation-diffusion correlation spectroscopy. In this way, we aim to detect a restricted diffusion microenvironment of CSF-like fluid (e.g. glymphatics) by employing wide regimes of relaxation and diffusion. To date, we have successfully imaged 9 lupus subjects and 9 controls using this protocol. We are also establishing advanced analysis pipelines for these novel datasets.					
<b>15. SUBJECT TERMS</b> Lupus, glymphatics, vasculature, brain, relaxation-diffusion correlation, VASO, MRI, tissue microenvironment					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  Unclassified	<b>18. NUMBER OF PAGES</b>  11	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified			<b>19b. TELEPHONE NUMBER (include area code)</b>

# TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	1
2. Keywords	1
3. Accomplishments	1-3
4. Impact	3
5. Changes/Problems	4
6. Products	5
7. Participants & Other Collaborating Organizations	6-8
8. Special Reporting Requirements	8
9. Appendices	8

## 1. INTRODUCTION:

This project applies novel brain imaging to detect and characterize the glymphatic system, a neurovascular component that may underlie mechanisms of pathology in neuropsychiatric lupus. Methods detect glymphatic flow-inducing vascular fluctuations due to respiration and cardiac cycles and the unique microenvironment of fluid-bearing glymphatic channels surrounding blood vessels. With these new measures, we are comparing lupus patients to matched healthy controls.

## 2. KEYWORDS:

Lupus, glymphatics, vasculature, brain, relaxation-diffusion correlation, VASO, MRI, tissue microenvironment

## 3. ACCOMPLISHMENTS:

### What were the major goals of the project?

Original goals for Aim 1: Develop and install three MRI approaches to characterize the glymphatic system: 1. CSF-spin labeling, 2. Ultra-high b-value DWI, 3. VASO correlated to respiration. Obtain local IRB and HRPO approval. (complete by end of November 2018)  
 Status of Aim 1: Development effort led to abandonment of CSF-spin labeling in favor of expanding the multiple b-value DWI approach to perform relaxation-diffusion correlation spectroscopy along dimensions of b-value, echo time (TE, for T2 relaxometry), and inversion time for T1 relaxometry. VASO was developed with respiration, cardiac, and CO2 monitoring. These are challenging approaches and they were developed and tested throughout the winter and installed in final form in May 2019. Local IRB approval was obtained in December 2018. HRPO approval was obtained mid-January 2019.

Original goals for Aim 2: Compare 16 lupus patients to 16 healthy controls using the new imaging protocol. Complete imaging acquisition by beginning of August 2019 and complete analysis by end of August 2019.  
 Status of Aim 2: As of September 27, 2019, 4 lupus patients successfully scanned. Recruitment of remaining lupus patients and matched controls ongoing. Streamlined analysis pipeline development underway.  
 No-Cost Extension requested May 2019 and granted June 2019 for one year: September 1, 2019 to August 31, 2020.  
 October 2019–January 2020: recruitment efforts continued, with modifications for PedANAM cognitive test requirements, and expanded advertisement materials.  
 January 2020–February 2020: 3 more lupus patients enrolled and imaged.  
 March 2020: COVID-19 shutdown of research MRI.  
 No-Cost Extension requested July 2020 and granted August 2020 for one year: September 1, 2020 to August 31, 2021.  
 September 2020: partial resumption of research MRI activities.  
 September 2020 – August 2021: total of 9 lupus and 9 controls scanned.  
 No-Cost Extension requested July 2021 and granted August 2021 for one year: September 1, 2021 to August 31, 2022.

### What was accomplished under these goals?

1) major activities: development and installation of new imaging protocols for assessment of glymphatic structure and function. Compare these assessments between lupus and healthy controls.

2) objectives: Be the first to use MRI to characterize the glymphatic system in humans and to gather the first evidence that glymphatic disruption may contribute to the pathology of neuropsychiatric lupus.

3) outcomes to date: while the general imaging approach did not change, our development efforts resulted in a change in strategy to detect glymphatic-specific microstructure: relaxation-diffusion correlation spectroscopy along T1, T2, and diffusion dimensions. This approach has been described in animals, but we adopted it for humans with challenging extensions of relaxation/diffusion regimes to capture glymphatic properties. We also developed the VASO method using a short TR and with concurrent monitoring of respiratory, cardiac, and CO2 variations. Nine lupus patients and 9 healthy controls have been scanned to date and recruitment continues for both lupus patients and healthy controls. Extended advertisement materials have been approved by the IRB. We have accumulated over 140 names for recruitment of matched controls. Modification for more liberal lupus inclusion approved (allowing SLEDAI >4 with one clinical feature as well as SLEDAI >6). COVID-19 has resulted in challenging recruitment conditions, especially for lupus patients, as many, now opt for telemedicine and are less willing to visit the research facility. This may be especially true for those patients with higher disease activity.

#### **What opportunities for training and professional development has the project provided?**

This project was not intended to provide training. A University of Cincinnati medical physics graduate student, Steven Ewart, took an interest in the project during its early stages. COVID-19 interrupted Steven's participation and he has since not resumed contact with the research team. Several internal presentations continue to be given covering the objectives and strategy of the project. Most notably, these have been given to members of the Rheumatology and Radiology Departments at Cincinnati Children's Hospital.

#### **How were the results disseminated to communities of interest?**

Nothing to Report

**What do you plan to do during the next reporting period to accomplish the goals?**

1) With the protocol installed, we continue to strive to maintain recruitment to achieve our goal of completing image acquisition for 16 lupus and 16 healthy control subjects. Target completion date is August 2022, with approval of a no-cost extension. As mentioned above, extended advertisement materials have been deployed. We have accumulated over 140 names for recruitment of controls, matched to the lupus patients. More liberal lupus inclusion is in place (allowing SLEDAI >4 with one clinical feature as well as SLEDAI >6) to increase lupus enrollment. Due to the ongoing challenges of COVID-19 and telemedicine for recruitment, the research team now plans to remove specific SLEDAI score criteria for inclusion. Our current experience suggest that this will substantially increase recruitment rate for lupus patients.

2) Optimization of the analysis pipeline will continue. This includes VASO analysis to extract both respiratory and cardiac contributions to blood vessel volume fluctuations. It will also include analysis to extract specific micro-environment properties adopted from the "MADCO" approach (e.g. Benjamini and Basser, Neuroimage (2017) 163: 183-196).

**4. IMPACT:**

**What was the impact on the development of the principal discipline(s) of the project?**

The imaging methods developed for this project may be the first to detect and to provide quantitative measures of a system (glymphatics) in the brain that is purported to have a role in clearing debris and maintaining immunological function. Lupus is known to degrade vasculature and may lead to neurodegeneration by disruption of the glymphatic system. Detection of this process would have a large impact on the study and treatment of lupus by providing a new route for early pathogenesis and a promising brain biomarker for early disease.

**What was the impact on other disciplines?**

Other neurodegenerative disorders may have a pathological pathway that includes degradation of vascular integrity and the associated glymphatic system. These include small vessel disease, Alzheimer's Disease, Parkinson's Disease, diabetes, chronic hypoxia (sleep apnea), and traumatic brain injury.

**What was the impact on technology transfer?**

If this pilot work leads to larger studies, the methodology could eventually enter clinical radiology practice for lupus and other neurovascular disorders.

**What was the impact on society beyond science and technology?**

Nothing to Report

## 5. CHANGES/PROBLEMS:

### Changes in approach and reasons for change .

Though our imaging protocol development effort resulted in some changes in approach from our original proposal, these changes did not result in significant deviation from the scope or objectives of the study.

### Actual or anticipated problems or delays and actions or plans to resolve them

Inadequate recruitment rate remains a concern, especially in light of ongoing potential disruption by COVID-19. Our institution is ahead of many with respect to reinstating research activities, although with some restrictions.

We continue to be engaged in weekly meetings to discuss recruitment strategy and status. We have determined that removal of strict SLEDAI score criteria should substantially increase recruitment rate for the lupus cohort. Lupus patients will still have active disease and dropping the score requirement will not impact the study's objectives.

We will also continue to boost advertisement for the project and to disseminate materials in more clinical and community sites.

Our ambitious data collection and analysis plan may not produce the glymphatic-specific signature we seek. The limited analyses to date suggest we may be detecting a confined CSF-like component in the microstructure, but more complete analyses are still necessary. The data are nevertheless rich and offer the potential for a variety of analysis approaches.

### Changes that had a significant impact on expenditures

Nothing to Report

### Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

#### Significant changes in use or care of human subjects

Nothing to Report

#### Significant changes in use or care of vertebrate animals

Nothing to Report

#### Significant changes in use of biohazards and/or select agents

Nothing to Report

## 6. PRODUCTS:

- **Publications, conference papers, and presentations**

*Report only the major publication(s) resulting from the work under this award.*

### **Journal publications.**

Nothing to Report

### **Books or other non-periodical, one-time publications.**

Nothing to Report

### **Other publications, conference papers and presentations.**

Nothing to Report. Only internal presentations.

- **Website(s) or other Internet site(s)**

Nothing to Report

- **Technologies or techniques**

Besides the new imaging protocol for MRI and potentially new analysis methods, nothing to report. Nothing shared.

- **Inventions, patent applications, and/or licenses**

Nothing to Report

- **Other Products**

Nothing to report yet that has been disseminated.  
Potential for new imaging sequences and tissue microstructure models.

## 7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

### What individuals have worked on the project?

Mark DiFrancesco, PhD. PI, 1.5 months  
Experiment design, development of imaging protocol, image acquisition, analysis development.

Hermine Brunner, MD, 1 month  
Subject recruitment, neuropsychological testing

Gregory Lee, PhD, worked on original development of imaging protocol.  
Dr. Lee has left Cincinnati Children's Hospital and no longer works on the project.

Jamie Meyers-Eaton, (coordinator) 2.5 months  
(replaced Arjun Mather)  
Study coordination, IRB communications, data acquisition, ushering of subjects through neuropsychological testing and imaging.

Research Associate and Biostatistician Mekibib Altaye: < 1 month.  
Experiment design, statistical consultation and support.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

**Mark DiFrancesco**

New

**Strauss Award (Brady)** 07/01/2021 – 06/30/2022 0.62 calendar  
CCHMC

**PORTICO Pilot (DiFrancesco)** 07/01/2021 – 06/30/2022 0.0 calendar  
NIH/MIAMS P30AR076316

Completed

**R01 HD086011 (Horowitz-Kraus)** 06/21/2016 – 05/31/2021 0.6 calendar  
NIH/NICHD

**Hermine Brunner**

New

**Falk Catalyst Award (Brunner)** 11/30/2020 – 11/29/2021 1.2 calendar  
Falk Medical Research Trust

Completed

**P50 DK096418 (Devarjan)** 09/01/2019-08/31/2021 0.6 calendar  
NIH/NIAMS

**R34 AR071651 (Brunner)** 06/01/2018-02/29/2021 1.80 calendar  
NIH/NIAMS

**Mekibib Altaye**

New

**R01EB029944 (He)** 09/30/2020 – 06/30/2024 0.6 calendar  
NIH/NIBIB

**1R01MH123831-01 (Tamm/Epstein)** 07/01/2020 -- 06/30/2025 0.12 calendar  
NIH/NIMH

Completed

**R01 HD086011 (Horowitz-Kraus)** 06/21/2016 – 05/31/2021 0.6 calendar  
NIH/NICHD

**R01 ES027224 (Yolton)** 09/30/2016 – 08/31/2021 1.8 calendar  
NIH/NIEHS

**R01 NS096037 (Parikh)** 09/30/2016 – 05/31/2021 0.48 calendar  
NIH/NINDS

**R21 HD094085 (He)** 08/01/2018 – 07/31/2020 0.48 calendar  
NIH

**R15 DC017280 (Dietz/Vannest)** 09/01/2018 – 08/31/2021 0.48 calendar  
NIH/UC

**What other organizations were involved as partners?**

Nothing to Report

**8. SPECIAL REPORTING REQUIREMENTS**

**COLLABORATIVE AWARDS:** Not applicable.

**QUAD CHARTS:** Not applicable.

**9. APPENDICES:** none